TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9438743

Group type: EXPERIMENTAL
Intervention: Active drug run-in period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reported results of studies with run-in periods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Results without run-in period
Number of subjects: 0
Study: 7699089

Group type: EXPERIMENTAL
Intervention: Transcranial color-coded sonography (TCCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transcranial Doppler (TCD)
Number of subjects: 20
Study: 2703763

Group type: EXPERIMENTAL
Intervention: Swimming in chlorinated water (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (pre-swimming assessment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Swimming in chlorinated water (Group 2)
Number of subjects: 30
Study: 851303

Group type: EXPERIMENTAL
Intervention: High-glucose-concentration dialysate (717 mg/dl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous mannitol (1g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of high-glucose-concentration dialysate and intravenous mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (regular dialysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-glucose-concentration dialysate and intravenous mannitol
Number of subjects: 0
Study: 31304909

Group type: COMPARATOR
Intervention: 100% nitrogen application in control environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 33% nitrogen application in manure environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 66% nitrogen application in compost environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vermicompost fertilizer and Azosperillum + Azotobacter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different levels of nitrogen fertilizer
Number of subjects: 0
Study: 29945920

Group type: EXPERIMENTAL
Intervention: Iberdomide (0.03-6 mg, n=6 across seven cohorts)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Iberdomide (0.03-6 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Iberdomide (0.3-6 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n=2/cohort)
Number of subjects: 56
Study: 26787147

Group type: EXPERIMENTAL
Intervention: Rapid Scale-Up (RSU) program
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison area (no RSU program)
Number of subjects: 9
Study: 25331767

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22360996

Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times per week daily in-center hemodialysis)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (6 times per week nocturnal hemodialysis)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 332
Study: 20175405

Group type: EXPERIMENTAL
Intervention: Selective SWS disruption by acoustic stimuli
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no disruption)
Number of subjects: 110
Study: 18063446

Group type: EXPERIMENTAL
Intervention: Virosomal subunit influenza vaccine (vSIV, brand: Invivac)
Number of subjects: 386

Group type: COMPARATOR
Intervention: MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Conventional subunit influenza vaccine (SIV, brand: Influvac)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Virosomal subunit influenza vaccine (vSIV)
Number of subjects: 386
Study: 15606445

Group type: EXPERIMENTAL
Intervention: NMI 861
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11879828

Group type: EXPERIMENTAL
Intervention: Intramedullary hip screw (IMHS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Compression hip screw (CHS)
Number of subjects: 102
Study: 10527227

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (10 microg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IT placebo
Number of subjects: 40
Study: 8669361

Group type: EXPERIMENTAL
Intervention: Conscious sedation by means of intravenous midazolam (0.1 mg/kg)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Local anaesthesia only
Number of subjects: 426
Study: 2045854

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy for 12 courses
Number of subjects: 486

Group type: COMPARATOR
Intervention: CMF chemotherapy for 8 courses followed by Adriamycin for 4 courses
Number of subjects: 486
Study: 7319877

Group type: COMPARATOR
Intervention: Slow isokinetic training at 60 degrees/s
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed isokinetic training at 60 and 300 degrees/s
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fast isokinetic training at 300 degrees/s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo group receiving low‐level muscle stimulation
Number of subjects: 0
Study: 31035054

Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chemical constituents of DHI (danshensu; lithospermic acid, LA; salvianolic acid D, SaD)
Number of subjects: 42
Study: 29263483

Group type: EXPERIMENTAL
Intervention: Staged-hybrid coronary revascularization (staged-HCR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimally invasive total arterial revascularization with BITA
Number of subjects: 70
Study: 25733743

Group type: EXPERIMENTAL
Intervention: Group music therapy (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (n = 100)
Number of subjects: 200
Study: 25158767

Group type: EXPERIMENTAL
Intervention: Shaped implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Round implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study: 22435856

Group type: EXPERIMENTAL
Intervention: ScvO(2) goal achievement (≥70%)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Lactate clearance (LC) goal achievement (≥10% decrease)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: No agreement between LC and ScvO(2) goal achievement
Number of subjects: 203
Study: 19187400

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 57
Study: 17133582

Group type: EXPERIMENTAL
Intervention: Pramipexole (median dose 0.35 mg/day)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo (median dose 0.47 mg/day)
Number of subjects: 345
Study: 15878754

Group type: EXPERIMENTAL
Intervention: VEGF gene polymorphism (BstUI C/T) in patients with oral cancer
Number of subjects: 367

Group type: COMPARATOR
Intervention: Normal control group (healthy individuals)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: T/C ratio in patients with oral cancer
Number of subjects: 367
Study: 11955903

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 40
Study: 9592637

Group type: EXPERIMENTAL
Intervention: Moderate exercise on a treadmill during hypoglycaemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest during hypoglycaemia
Number of subjects: 10
Study: 7618721

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 27
Study: 1282616

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg, twice daily for 21 days)
Number of subjects: 16
Study: 6369366

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30797386

Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couple Therapy (ABCT)
Number of subjects: 188
Study: 29509108

Group type: EXPERIMENTAL
Intervention: Photograph-based telemedicine review
Number of subjects: 37
Study: 26781428

Group type: EXPERIMENTAL
Intervention: 10% decrease in colonoscopy reimbursement
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 20% decrease in colonoscopy reimbursement
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 30% decrease in colonoscopy reimbursement
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 40% decrease in colonoscopy reimbursement
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Retirement plans after 2030
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 20% reimbursement reduction (retirement subgroup)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 30% reimbursement reduction (retirement subgroup)
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: 40% reimbursement reduction (retirement subgroup)
Number of subjects: 2009
Study: 25694481

Group type: EXPERIMENTAL
Intervention: High Sodium (HS) intake (7 days, 200 mmol Na(+)/24 h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low Sodium (Na) intake (7 days, 50 mmol Na(+)/24 h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ANG II infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (fHP women)
Number of subjects: 36
Study: 23496006

Group type: EXPERIMENTAL
Intervention: Soft music
Number of subjects: 93

Group type: COMPARATOR
Intervention: No music
Number of subjects: 93
Study: 19940229

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of golimumab 100 mg (30‐minute infusion, n = 23)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at upper arm (n = 18)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at abdomen (n = 18)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of golimumab 100 mg at thigh (n = 19)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Overall SC administration of golimumab 100 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of golimumab 100 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of golimumab 100 mg
Number of subjects: 78
Study: 18379535

Group type: EXPERIMENTAL
Intervention: Icodextrin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose solutions
Number of subjects: 0
Study: 16802519

Group type: EXPERIMENTAL
Intervention: Beta-blockers, ACE inhibitors/AT1 receptor antagonists, diuretics, aldosterone antagonists, and glycosides (specific dosages and durations not available)
Number of subjects: 0
Study: 14581346

Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib once a day for 9 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib once a day
Number of subjects: 21
Study: 10947698

Group type: COMPARATOR
Intervention: Caudal ropivacaine 0.2% 1 ml/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Caudal ropivacaine 0.2% 1 ml/kg plus caudal ketamine 0.25 mg/kg
Number of subjects: 32
Study: 9224783

Group type: EXPERIMENTAL
Intervention: [14C]avitriptan 20 mg/kg iv and oral in rats; 10 mg iv and 50 mg oral in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [14C]avitriptan
Number of subjects: 0
Study: 8095240

Group type: EXPERIMENTAL
Intervention: formoterol (24 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: salbutamol (400 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: fenoterol (400 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3689015

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 1030
Study: 30124733

Group type: EXPERIMENTAL
Intervention: Nature-based regimen (NR) containing natural oils, beeswax, and witch hazel, and day & night creams containing natural oils, glycerin, and botanical anti-inflammatories
Number of subjects: 120

Group type: COMPARATOR
Intervention: Synthetic dermatologist-recommended regimen (CR) containing cetyl alcohol, sodium lauryl sulphate-containing cleanser and glycerin, polyisobutene-containing lotion
Number of subjects: 120
Study: 26950097

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group therapy (CBGT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mindfulness‐based stress reduction (MBSR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 108
Study: 24554416

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR) program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 15
Study: 22843010

Group type: EXPERIMENTAL
Intervention: Salicylic sugar powder
Number of subjects: 143

Group type: COMPARATOR
Intervention: Natural drying
Number of subjects: 143

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 143
Study: 20819314

Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN-gamma injection
Number of subjects: 148
Study: 17670998

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1801
Study: 15604156

Group type: EXPERIMENTAL
Intervention: Standardised safety consultation and provision of safety equipment (stair gates, fire guards, smoke alarms, cupboard locks, window locks)
Number of subjects: 3428

Group type: EXPERIMENTAL
Intervention: Standardised safety consultation and provision of safety equipment
Number of subjects: 3428

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3428
Study: 12396255

Group type: EXPERIMENTAL
Intervention: Unusual experiences
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Impulsive non-conformity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive disorganization
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Introvertive anhedonia
Number of subjects: 80
Study: 8311216

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 3138441

Group type: EXPERIMENTAL
Intervention: BCAA-enriched amino acid solution
Number of subjects: 173
Study: 31034264

Group type: EXPERIMENTAL
Intervention: 12-weeks moderate-intensity resistance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 24
Study: 30852469

Group type: EXPERIMENTAL
Intervention: Finger tapping training with a metronome set to 20% faster pace than pre-training walking cadence
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Arm swing training with a metronome
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 41
Study: 27768643

Group type: EXPERIMENTAL
Intervention: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation without intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcanalicular laser‐assisted dacryocystorhinostomy with endonasal augmentation with bicanalicular intubation
Number of subjects: 60
Study: 26071234

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1820

Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1820
Study: 23259514

Group type: EXPERIMENTAL
Intervention: Kava (180 mg of kavalactones)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21620099

Group type: EXPERIMENTAL
Intervention: Biopsy group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 19452698

Group type: EXPERIMENTAL
Intervention: Lumbar traction for 24 weeks
Number of subjects: 263

Group type: COMPARATOR
Intervention: Sertraline hydrochloride tablets for 24 weeks
Number of subjects: 263
Study: 16412876

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stents (SES)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 322
Study: 15221403

Group type: EXPERIMENTAL
Intervention: Passive torque at 63% of v(max)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Size-normalized passive torque at 63% of v(max)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Size-normalized passive torque at 77% of v(max)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hydrostatic lift at 63% of v(max)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Passive torque and hydrostatic lift
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hydrostatic lift and passive torque
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Corrected for body size
Number of subjects: 22
Study: 11726450

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 0.5 microg/mL sufentanil (BS group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine plus 0.5 microg/mL sufentanil (RS group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.2% ropivacaine (R group)
Number of subjects: 60
Study: 9524436

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 171)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (n = 189)
Number of subjects: 360
Study: 8478307

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily for 7 days
Number of subjects: 304

Group type: COMPARATOR
Intervention: Erythromycin 250 mg four times daily for 7 days
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily for 7 days (European study)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Erythromycin (European study)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Dirithromycin 500 mg once daily for 7 days (Italian study)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Miocamycin 600 mg twice daily for 7 days (Italian study)
Number of subjects: 304
Study: 3072779

Group type: EXPERIMENTAL
Intervention: Closure and vagotomy (truncal vagotomy in 71 patients, proximal gastric vagotomy in 8 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Closure and vagotomy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Definitive surgery (closure and vagotomy)
Number of subjects: 162
Study: 31634080

Group type: EXPERIMENTAL
Intervention: Resilient students
Number of subjects: 117539

Group type: EXPERIMENTAL
Intervention: Low performing students
Number of subjects: 117539

Group type: EXPERIMENTAL
Intervention: Student confidence with reading
Number of subjects: 117539

Group type: EXPERIMENTAL
Intervention: Early literacy activities
Number of subjects: 117539
Study: 28520754

Group type: EXPERIMENTAL
Intervention: IWT + high-dose post-exercise milk product intake (HD, n = 13)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: IWT + low-dose post-exercise milk product intake (LD, n = 12)
Number of subjects: 37

Group type: COMPARATOR
Intervention: IWT alone (CNT, n = 12)
Number of subjects: 37
Study: 26171983

Group type: EXPERIMENTAL
Intervention: Intranasal 8 IU OT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intranasal 24 IU OT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous 1 IU OT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22157215

Group type: EXPERIMENTAL
Intervention: SLNB+ALND (GrA)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: SLNB+ALND (GrB)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Delayed ALND (SubGrB2a)
Number of subjects: 199

Group type: COMPARATOR
Intervention: SLNB (SubGrB2b)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Node-negative ALND (SubGrA2)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Node-positive ALND (A1+B1+B2a)
Number of subjects: 199
Study: 22978443

Group type: EXPERIMENTAL
Intervention: Research arms (specific arms not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New research arm (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 19566638

Group type: EXPERIMENTAL
Intervention: Support program for stress management (homework for 3 months, nurse feedback monthly)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Support program for stress management
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (only booklet)
Number of subjects: 140
Study: 17513626

Group type: EXPERIMENTAL
Intervention: Caudal clonidine (2 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal morphine (50 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caudal hydromorphone (10 mcg/kg) combined with 1.0 mL/kg of 0.2% ropivacaine with epinephrine
Number of subjects: 60
Study: 15593020

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone with chlorambucil or cyclophosphamide (6-month treatment alternating every other month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long acting ACTH preparation (1 year treatment)
Number of subjects: 0
Study: 11437859

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 299
Study: 9931685

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine substitution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 7823566

Group type: COMPARATOR
Intervention: Connected speech fragments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 msec vowel onset stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 msec post-onset stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 msec whole vowel stimulus
Number of subjects: 0
Study: 3346287

Group type: EXPERIMENTAL
Intervention: Sliding screw‐plate device
Number of subjects: 127

Group type: COMPARATOR
Intervention: Double divergent pins
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 127
Study: 29564625

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 108

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 108
Study: 28204912

Group type: EXPERIMENTAL
Intervention: High-fat/calorie meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-fat/calorie meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate-fat/standard-calorie meals
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fasted condition
Number of subjects: 28